Veracyte Announces Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Veracyte (VCYT) Tops Q3 EPS by 13c, Revenues Beat; Boosts FY18 Revenue Outlook
October 29, 2018 4:30 PM EDTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.12), $0.13 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $21.5 million.
Revenue was $23.5 million, an increase of 34 percent;Genomic test volume was 8,006, an increase of 23 percent;Gross margin was 65 percent, an increase of 6 percent;Operating expenses,... More